Cargando…

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV

The widespread use of highly active antiretroviral treatments has dramatically changed the prognosis of people living with HIV (PLWH). However, such treatments have to be taken lifelong raising issues regarding the maintenance of both therapeutic effectiveness and long‐term tolerability. Recently ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courlet, Perrine, Alves Saldanha, Susana, Cavassini, Matthias, Marzolini, Catia, Choong, Eva, Csajka, Chantal, Günthard, Huldrych F., André, Pascal, Buclin, Thierry, Desfontaine, Vincent, Decosterd, Laurent Arthur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317362/ https://www.ncbi.nlm.nih.gov/pubmed/32160389 http://dx.doi.org/10.1002/jms.4506

Ejemplares similares

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
por: Thoueille, Paul, et al.
Publicado: (2022)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV
por: Stader, Felix, et al.
Publicado: (2021)

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration
por: Thoueille, Paul, et al.
Publicado: (2023)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma
por: Spaggiari, Dany, et al.
Publicado: (2019)

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
por: Smith, Steven J., et al.
Publicado: (2018)

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model
por: Mohan, Haneesha, et al.
Publicado: (2022)

Dynamic profiling of intact glucosinolates in radish by combining UHPLC-HRMS/MS and UHPLC-QqQ-MS/MS
por: Yan, Chenghuan, et al.
Publicado: (2023)

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants
por: Snedecor, Sonya J, et al.
Publicado: (2021)

Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
por: Desfontaine, Vincent, et al.
Publicado: (2023)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
por: Oliveira, Maureen, et al.
Publicado: (2018)

Pharmacokinetics and Metabolism Study of Deep-Sea-Derived Butyrolactone I in Rats by UHPLC–MS/MS and UHPLC–Q-TOF-MS
por: Wu, Liang, et al.
Publicado: (2021)

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
por: Pintado, Claire, et al.
Publicado: (2020)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

Determination of iohexol by capillary blood microsampling and UHPLC-MS/MS
por: Ion, Valentin, et al.
Publicado: (2019)

Determination of Paraquat in Arabidopsis Tissues and Protoplasts by UHPLC-MS/MS
por: Zhao, Mingming, et al.
Publicado: (2023)

Comparison of Two Methods, UHPLC-UV and UHPLC-MS/MS, for the Quantification of Polyphenols in Cider Apple Juices
por: Verdu, Cindy F., et al.
Publicado: (2013)

Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
por: Thoueille, Paul, et al.
Publicado: (2021)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

1027. At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial
por: Williams, Jamila K, et al.
Publicado: (2023)

Simultaneous Determination of Structurally Diverse Compounds in Different Fangchi Species by UHPLC-DAD and UHPLC-ESI-MS/MS
por: Sim, Hee-Jung, et al.
Publicado: (2013)

Pharmacokinetics and Metabolism Research of Shenkang Injection in Rats Based on UHPLC-MS/MS and UHPLC-Q-Orbitrap HRMS
por: Jiang, Xiaofang, et al.
Publicado: (2020)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Determination of lesinurad in rat plasma by a UHPLC–MS/MS assay
por: Zhou, Xiao-Yang, et al.
Publicado: (2017)

Grape Lipidomics: An Extensive Profiling thorough UHPLC-MS/MS Method
por: Masuero, Domenico, et al.
Publicado: (2021)

Characterization of URB Series Synthetic Cannabinoids by HRMS and UHPLC–MS/MS
por: Agostini, Marco, et al.
Publicado: (2023)

Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy
por: Glass, Tracy R., et al.
Publicado: (2012)

Identification for metabolism profiles and pharmacokinetic studies of tradition Chinese prescription Ji-Ming-San and its major metabolites in rats by UHPLC-Q-TOF-MS/MS and UHPLC-MS/MS
por: Hsieh, Cheng-Yang, et al.
Publicado: (2023)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Immune Reconstitution Inflammatory Syndrome in Aids Patient After Successful Induction of Virological Suppression with Cabotegravir/Rilpivirine
por: Al-Handola, Rami, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_le56kcui4jtng2c40a7bqck8mi